Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS)

Pediatric Blood and Cancer

Volumn 52, Issue 2, 2009, Pages 186-190

  Dembowska Baginska, Bozenna ^a   Perek, Danuta ^a   Brozyna, Agnieszka ^a   Wakulinska, Anna ^a   Olczak Kowalczyk, Dorota ^a   Gladkowska Dura, Malgorzata ^a   Grajkowska, Wieslawa ^a   Chrzanowska, Krystyna H ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Chemotherapy; Congenital immunodeficiency; Nijmegen breakage syndrome; Non hodgkin lymphoma; Pediatric oncology; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSTATIC AGENT; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MALE; MULTIPLE NECROTIC SKIN ULCER; NIJMEGEN BREAKAGE SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEPSIS; SKIN ULCER; STOMATITIS; T CELL LYMPHOMA; THERAPY DELAY; THROMBOSIS; TREATMENT OUTCOME; ADOLESCENT; DOSE RESPONSE; REMISSION; RETROSPECTIVE STUDY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NIJMEGEN BREAKAGE SYNDROME; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59449104796     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21789     Document Type: Article

References (16)

1. Chrzanowska KH, Kleijer WJ, Krajewska-Walasek M, et al. Eleven patients with microcephaly, immunodeficiency and chromosomal instability. The Nijmegen breakage syndrome. Am J Med Genet 1995;57:462-471.
2. Meyn MS. Chromosome instability syndromes: Lessons for carcinogenesis. Curr Top Microbiol Immunol 1987;221:72-148.
3. Duker NJ. Chromosome breakage syndromes and cancer. Am J Med Genet 2002;115:125-129.
4. Filipowich AH. Primary immunodeficiencies: Genetic risk factors for lymphoma. Cancer Res 1992;52:5465-5467.
5. Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Hematol 2002;15:695-711.
6. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of children and adolescence: Results of a treatment stratified for biologic subtypes and stage - A report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995;13:359-372.
7. Seidemann K, Tiemann M, Henze G, et al. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: Analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999;33:536-544.
8. Seidemann K, Henze G, Beck JD, et al. Non-Hodgkin lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): Experience from the BFM trials. Ann Oncol 2000;11:141-145.
9. Pasic S, Vujic D, Fiorini M, et al. T-cell lymphoblastic leukemia/lymphoma in Nijmegen breakage syndrome. Haematologica 2004;89:ECR27.
10. Barth E, Demori E, Pecile V, et al. Anthracyclines in Nijmegen Breakage syndrome. Med Pediatr Oncol 2003;4:122-124.
11. Dumic M, Radman I, Krnic N, et al. Successful treatment of diffuse large B-cell non-Hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/ vincristine/prednisone) chemotherapy and rituximab in patient with Nijmegen syndrome. Clin Lymphoma Myeloma 2007;7:590-593.
12. Murphy SB. Classification, staging and end results of treatment in childhood non-Hodgkin lymphoma: Dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332.
13. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
14. Kruger L, Demuth D, Neitzel H, et al. Cancer incidence and Nijmegen breakage syndrome is modulated by the amount of a variant NBS protein. Carcinogenesis 2007;28:107-111.
15. Gladkowska-Dura M, Chrzanowska KH, Dura W. Malignant lymphoma in Nijmegen syndrome. Ann Pediatr Pathol 2000;4:39-46.
16. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hematopoietic stem cell transplantation. Clin Infect Dis 2007;45:1296-1304.